Forbes June 29, 2022
Robert Pearl, M.D.

Having worked in healthcare most of my life, very little surprises me. But four years ago, I was shocked by the unfiltered honesty of one drug-company CEO.

Asked to explain why he raised the price of an antibiotic by more than 400%, Nirmal Mulye, CEO of Nostrum Laboratories, told the Financial Times: “I think it’s a moral requirement to make money when you can … to sell the product for the highest price.”

The product Mulye mentioned wasn’t a new medication. He was talking about nitrofurantoin, a drug first created in 1953 to treat bladder infections. It sits on the World Health Organization’s list of essential medicines.

Mulye’s defense of a 400% drug price increase as a “moral requirement” made...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Pharma, Pharma / Biotech, Pricing / Spending
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours
Covid’s scientific silver lining: A chance to watch the human immune system respond in real time
How GLP-1’s moved from research labs to national TV
Understanding the politics of drug pricing in the United States
Opinion: Oprah kicked off a national conversation on obesity and GLP-1 drugs. Let’s have it

Share This Article